ConductScience.org, home

Paper40189932

PD-L1 Scoring Models for Non-Small Cell Lung Cancer in China: Current Status, AI-Assisted Solutions and Future Perspectives.

Huang Z and 4 others. Thorac Cancer, 2025. Cited by 4 papers, by iCite.

Cite this record

ConductScience Library. PD-L1 Scoring Models for Non-Small Cell Lung Cancer in China: Current Status, AI-Assisted Solutions and Future Perspectives. Papers, record 40189932. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40189932

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
PD-L1 Scoring Models for Non-Small Cell Lung Cancer in China: Current Status, AI-Assisted Solutions and Future Perspectives.
PubMed
Journal
Thorac Cancer
PubMed
Year
2025
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
4
iCite
Revised in PubMed
2025-05-16
PubMed

Authors5

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Huang ZZilinghttps://orcid.org/0000-0002-0899-1270
2Wang SShen
3Zhou JJiansong
4Chen HHaiquanhttps://orcid.org/0000-0001-7846-257X
5Li YYuan

Source PubMed

Download CSV of authors

Topics9

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Carcinoma, Non-Small-Cell LungMajor topic
Lung NeoplasmsMajor topic
B7-H1 AntigenMajor topic
Artificial IntelligenceMajor topic
Biomarkers, TumorMajor topic
Humans
China
Prognosis
Immunotherapy

Source PubMed

Download CSV of topics

Grants3

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
MSD ChinaPubMed
2021YFF1201001National Key Research and Development Program of ChinaPubMed
23XHYD-12The Institution and Governmental Cooperative Project, Shanghai Xuhui District Science and Technology CommitteePubMed

Source PubMed

Download CSV of grants

References107

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
133196892Clinicopathological and molecular characteristics associated with PD-L1 expression in non-small cell lung cancer: a large-scale, multi-center, real-world study in China.J Cancer Res Clin Oncol2021https://conductscience.org/library/papers/33196892PubMed
237383318Assessing the design of China's complex health system - Concerns on equity and efficiency.Health Policy Open2020https://conductscience.org/library/papers/37383318PubMed
336735893Pembrolizumab Plus Chemotherapy in Squamous Non-Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study.J Clin Oncol2023https://conductscience.org/library/papers/36735893PubMed
429389679Artificial Intelligence in Surgery: Promises and Perils.Ann Surg2018https://conductscience.org/library/papers/29389679PubMed
537924090Continuing medical education in China: evidence from primary health workers' preferences for continuing traditional Chinese medicine education.BMC Health Serv Res2023https://conductscience.org/library/papers/37924090PubMed
632842436[Expert consensus on PD-L1 expression testing in non-small-cell lung cancer in China].Zhonghua Zhong Liu Za Zhi2020https://conductscience.org/library/papers/32842436PubMed
732300181Prospective multi-institutional evaluation of pathologist assessment of PD-L1 assays for patient selection in triple negative breast cancer.Mod Pathol2020https://conductscience.org/library/papers/32300181PubMed
835840720Association of artificial intelligence-powered and manual quantification of programmed death-ligand 1 (PD-L1) expression with outcomes in patients treated with nivolumab ± ipilimumab.Mod Pathol2022https://conductscience.org/library/papers/35840720PubMed
925565398A nationwide telepathology consultation and quality control program in China: implementation and result analysis.Diagn Pathol2014https://conductscience.org/library/papers/25565398PubMed
1028885881Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.N Engl J Med2017https://conductscience.org/library/papers/28885881PubMed
1138983127Real‑world evidence of advanced non‑small cell lung carcinoma treated with an immune checkpoint inhibitor plus chemotherapy.Oncol Lett2024https://conductscience.org/library/papers/38983127PubMed
1234689789PD-L1 immunostaining: what pathologists need to know.Diagn Pathol2021https://conductscience.org/library/papers/34689789PubMed
1335174655The ethical challenges of artificial intelligence-driven digital pathology.J Pathol Clin Res2022https://conductscience.org/library/papers/35174655PubMed
1432007657Cytology for PD-L1 testing: A systematic review.Lung Cancer2020https://conductscience.org/library/papers/32007657PubMed
1534565707PD-L1 Expression and Comprehensive Molecular Profiling Predict Survival in Nonsmall Cell Lung Cancer: A Real-World Study of a Large Chinese Cohort.Clin Lung Cancer2022https://conductscience.org/library/papers/34565707PubMed
1639257157Regulating algorithmic care in the European Union: evolving doctor-patient models through the Artificial Intelligence Act (AI-Act) and the liability directives.Med Law Rev2025https://conductscience.org/library/papers/39257157PubMed
1733979398A fast and effective detection framework for whole-slide histopathology image analysis.PLoS One2021https://conductscience.org/library/papers/33979398PubMed
1831656061Interobserver Reproducibility of PD-L1 Biomarker in Non-small Cell Lung Cancer: A Multi-Institutional Study by 27 Pathologists.J Pathol Transl Med2019https://conductscience.org/library/papers/31656061PubMed
1937078210[Expert consensus on PD-L1 expression testing in esophageal carcinoma in China].Zhonghua Zhong Liu Za Zhi2023https://conductscience.org/library/papers/37078210PubMed
2027913228PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project.J Thorac Oncol2017https://conductscience.org/library/papers/27913228PubMed

See all 107 referencesDownload CSV of references

Cited by2

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 4 citations.

PMIDTitleJournalYearIn PapersSource
41357215Beyond monotherapy: multimodal strategies integrating immune checkpoint inhibitors in lymphoma management.Front Immunol2025https://conductscience.org/library/papers/41357215PubMed
40968169Enhanced patient selection with quantitative continuous scoring of PD-L1 expression for IO treatment in metastatic NSCLC.NPJ Precis Oncol2025https://conductscience.org/library/papers/40968169PubMed

Download CSV of cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
CD27429126PubTator's text mininghttps://conductscience.org/library/genes/29126

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/40189932

GET https://conductscience.org/api/papers/v1/40189932/references?page=2